mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation  by Morita, Masahiro et al.
Cell Metabolism
ArticlemTORC1 Controls Mitochondrial Activity
and Biogenesis through 4E-BP-Dependent
Translational Regulation
Masahiro Morita,1,2 Simon-Pierre Gravel,1,2 Vale´rie Che´nard,1,2 Kristina Sikstro¨m,3 Liang Zheng,4 Tommy Alain,1,2
Valentina Gandin,5,7 Daina Avizonis,2 Meztli Arguello,1,2 Chadi Zakaria,1,2 Shannon McLaughlan,5,7 Yann Nouet,1,2
Arnim Pause,1,2 Michael Pollak,5,6,7 Eyal Gottlieb,4 Ola Larsson,3 Julie St-Pierre,1,2,* Ivan Topisirovic,5,7,*
and Nahum Sonenberg1,2,*
1Department of Biochemistry
2Goodman Cancer Research Centre
McGill University, Montreal, QC H3A 1A3, Canada
3Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 171 76, Sweden
4Cancer Research UK, The Beatson Institute for Cancer Research, Switchback Road, Glasgow G61 1BD, Scotland, UK
5Lady Davis Institute for Medical Research
6Cancer Prevention Center, Sir Mortimer B. Davis-Jewish General Hospital
McGill University, Montreal, QC H3T 1E2, Canada
7Department of Oncology, McGill University, Montreal, QC H2W 1S6, Canada
*Correspondence: julie.st-pierre@mcgill.ca (J.S.-P.), ivan.topisirovic@mcgill.ca (I.T.), nahum.sonenberg@mcgill.ca (N.S.)
http://dx.doi.org/10.1016/j.cmet.2013.10.001SUMMARY
mRNA translation is thought to be the most energy-
consuming process in the cell. Translation and
energy metabolism are dysregulated in a variety of
diseases including cancer, diabetes, and heart
disease. However, the mechanisms that coordinate
translation and energy metabolism in mammals
remain largely unknown. The mechanistic/mamma-
lian target of rapamycin complex 1 (mTORC1) stimu-
latesmRNAtranslationandother anabolicprocesses.
We demonstrate that mTORC1 controls mitochon-
drial activity and biogenesis by selectively promoting
translation of nucleus-encodedmitochondria-related
mRNAs via inhibition of the eukaryotic translation
initiation factor 4E (eIF4E)-binding proteins (4E-
BPs). Stimulating the translation of nucleus-encoded
mitochondria-related mRNAs engenders an increase
in ATP production capacity, a required energy source
for translation. These findings establish a feed-for-
ward loop that links mRNA translation to oxidative
phosphorylation, thereby providing a keymechanism
linking aberrant mTOR signaling to conditions of
abnormal cellular energy metabolism such as
neoplasia and insulin resistance.
INTRODUCTION
Translation is considered to be one of the most energy-
consuming cellular processes, accounting for 20%–30% of
total ATP consumption, not including the energy expended dur-
ing the biosynthesis of rRNA (Buttgereit and Brand, 1995; Rolfe
and Brown, 1997). Mitochondria are the main producers of698 Cell Metabolism 18, 698–711, November 5, 2013 ª2013 ElsevierATP under physiological conditions in mammals and play a crit-
ical role in overall energy balance (Vander Heiden et al., 2009).
The mechanistic/mammalian target of rapamycin (mTOR) is a
serine/threonine kinase that has been implicated in a variety of
physiological processes and pathological states (Zoncu et al.,
2011). mTOR forms two distinct complexes, mTOR complex 1
(mTORC1) and 2 (mTORC2), which differ in their composition,
downstream targets, regulation, and sensitivity to the allosteric
inhibitor rapamycin (Hara et al., 2002; Kim et al., 2002; Sarbas-
sov et al., 2004). mTORC1 stimulates mRNA translation and
other anabolic processes (e.g., lipogenesis) in response to a
variety of extracellular signals and intracellular cues such as
nutrients, oxygen, and hormones (Laplante and Sabatini, 2012;
Yecies and Manning, 2011). mTORC2 controls cell survival,
cytoskeleton organization (Jacinto et al., 2004; Sarbassov
et al., 2004), lipogenesis, and gluconeogenesis (Hagiwara
et al., 2012; Yuan et al., 2012) by activating AGC kinases
including serum- and glucocorticoid-regulated kinase (SGK)
and AKT (Garcı´a-Martı´nez and Alessi, 2008; Ikenoue et al.,
2008; Sarbassov et al., 2005). Hyperactivation of mTORC1
frequently accompanies diseases characterized by perturba-
tions in energy metabolism and translation including cancer
and the metabolic syndrome (Laplante and Sabatini, 2012).
mTORC1 stimulates translation by phosphorylating down-
stream targets including 4E-BPs and ribosomal protein S6
kinases (S6Ks) (Roux and Topisirovic, 2012). Phosphorylation
of 4E-BPs by mTORC1 leads to their dissociation from eIF4E,
thereby allowing association of eIF4E with eIF4G and the
assembly of the eIF4F translation initiation complex at the
mRNA 50 end (Gingras et al., 1999, 2001; Pause et al., 1994).
S6Ks phosphorylate components of the translational machinery
and associated factors such as ribosomal protein S6, eIF4B, and
PDCD4 (Banerjee et al., 1990; Dorrello et al., 2006; Kozma et al.,
1990; Shahbazian et al., 2006). mTORC1 also controls energy
metabolism by stimulating the activity of several transcriptional
regulators such as PPARg coactivator-1a (PGC-1a), sterolInc.
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mTORC1/4E-BP Controls Mitochondrial Functionregulatory element-binding protein 1/2 (SREBP1/2), and hypoxia
inducible factor-1a (HIF-1a) (Cunningham et al., 2007; Du¨vel
et al., 2010; Porstmann et al., 2008). Therefore, mTORC1 is
thought to be an integral node in a network that couples cellular
energy production to consumption.
In this study, we demonstrate that mTORC1 stimulates
mitochondrial biogenesis and activity, thereby bolstering ATP
production capacity. mTOR inhibitors caused a decrease in
ATP levels associated with impaired mitochondrial function and
glycolysis. At the molecular level, this is explained by preferential
inhibition of translation of a subset of cellularmRNAs that encode
for essential nucleus-encoded mitochondrial proteins including
the components of complex V and TFAM (transcription factor
a, mitochondrial). Moreover, we show that 4E-BPs mediate the
stimulatory effect of mTORC1 on the translation of mitochon-
dria-related mRNAs, mitochondrial respiration and biogenesis,
and ATP production in vitro and in vivo. These data reveal a
feed-forward mechanism by which translation impacts mito-
chondrial function to maintain energy homeostasis in the cell.
RESULTS
mTOR Regulates Translation of a Subset
of Mitochondria-Related mRNAs
We recently identified mRNAs whose translation was affected
by mTOR inhibitors (Larsson et al., 2012) using genome-
wide polysome profiling (Larsson et al., 2010, 2011). Among
the mRNAs whose translation was suppressed after 12 hr treat-
ment with the active-site mTOR inhibitor (asTORi) PP242, those
encoding mitochondria-related proteins were highly abundant
(14% of target mRNAs) (Table S1). Indeed, pathway analysis us-
ing the generally applicable gene-set enrichment (GAGE)
method (Luo et al., 2009) revealed a significant enrichment of
genes annotated to mitochondria-related functions as transla-
tionally suppressed by PP242 (Figure 1A). mRNAs encoding
components of complex V (ATP synthase) in the oxidative phos-
phorylation pathway were the most significantly enriched (Fig-
ure 1A) and included ATP synthase subunit delta (ATP5D),
ATP5G1, ATP5L, and ATP5O (Figure 1B) (Hoffmann et al.,
2010). mRNAs encoding TFAM (transcription factor A, mito-
chondrial), which promotes mitochondrial DNA replication and
transcription (Bonawitz et al., 2006), mitochondrial ribosomal
proteins, and NADH dehydrogenase 1 alpha subcomplex as-
sembly factors 2 and 4 (NDUFAF2 and 4), were also significantly
enriched (Figures 1A and 1B).
mTOR also regulates transcription of mitochondrial genes via
PGC-1a (Bla¨ttler et al., 2012; Cunningham et al., 2007). Potential
effects of mTOR inhibition on mitochondrial function that are
caused by transcriptional mechanisms could therefore obscure
those that occur at the level of translation. To exclude this
possibility, we compared the effects of PP242 on transcriptional
and translational activity, which revealed that after 12 hr treat-
ment PP242 strongly inhibited translation of a subset of mito-
chondria-related mRNAs, while having only a marginal effect
on transcription of the corresponding genes (Figure 1C). Consis-
tently, the assessment of mitochondrial functions upon ectopic
expression of the transcriptional coactivators (e.g., PGC-1a)
has typically been performed after 48 hr or longer (Lehman
et al., 2000; St-Pierre et al., 2003). Thus, 12 hr asTORi treatmentCell Mis adequate to determine the effects of translation on mitochon-
drial activity, without substantial interference from transcrip-
tional mechanisms.
We next validated the effect of two asTORi: Ink1341 (derived
from the PP242 chemical scaffold [Alain et al., 2012]) and Torin1
(Thoreen et al., 2009) on the translation of several mitochondria-
related mRNAs in MCF7 cells using polysome profiling. As
reported previously (Thoreen et al., 2009; Yu et al., 2009), the
phosphorylation of 4E-BP1, 4E-BP2, and ribosomal protein S6
was abolished by asTORi (Figure 2A). Accordingly, asTORi
strongly impaired the eIF4F complex assembly as monitored
by a cap pull-down assay (Figure 2B). To directly investigate
whether asTORi suppress translation of mitochondria-related
mRNAs, polysomes from MCF7 cells treated with asTORi were
sedimented in sucrose density gradients to separate efficiently
translated mRNAs (associated with heavy polysomes) from
those that are poorly translated (associated with light poly-
somes) (Figure 2C). asTORi inhibited protein synthesis, as illus-
trated by the decrease in polysome content with a concomitant
increase in the 80S peak (Figure 2C). Consistent with previous
findings (Alain et al., 2012; Hsieh et al., 2012; Thoreen et al.,
2012), Ink1341 and Torin1 did not induce complete disassembly
of polysomes (Figure 2C), indicating that these compounds
selectively block translation of a subset of mRNAs. Indeed,
12 hr Torin1 treatment caused a35% decrease in global trans-
lation relative to a control as measured by [35S]methionine/
cysteine labeling (Figure S1). Thus, we assessed the effects of
Ink1341 and Torin1 on polysomal distribution of ATP5O,
ATP5D, and TFAM mRNAs, which were identified as mTOR-
sensitive (Figure 1B), and b-actin mRNA, which is resistant to
mTOR inhibitors (Hsieh et al., 2012; Larsson et al., 2012). asTORi
suppressed translation of ATP5D, ATP5O, and TFAMmRNAs, as
illustrated by a shift of these mRNAs toward lighter polysomes
(Figure 2D), whereas asTORi failed to shift the b-actin mRNA
(Figure 2D). Consistently, ATP5O, ATP5D, and TFAM but not
b-actin protein levels were decreased in asTORi-treated cells
(Figure 2A). In contrast to ATP5O, ATP5D, and TFAM, expression
of COX4I1 protein that is a component of oxidative
phosphorylation complex IV (Fornuskova et al., 2010) was not
sensitive to asTORi (Figure 2A). These data indicate that mTOR
controls translation of a subset of, but not all, mitochondria-
related mRNAs.
mTOR Controls Mitochondrial Function and ATP
Production
Since asTORi inhibited translation of ATP5D, ATP5O, and TFAM
mRNAs, we wished to investigate the effects of asTORi on mito-
chondrial activity. MCF7 cells were treated with a vehicle, PP242
or Ink1341, for 12 hr, and the rate of mitochondrial respiration
was determined using a Clark-type electrode (Figures 3A–3D).
asTORi decreased total mitochondrial respiration (35%) as
compared to vehicle control (Figure 3A). There are two types of
mitochondrial respiration: coupled respiration (drives oxidative
phosphorylation and ATP synthesis) and uncoupled respiration
(represents proton leak reactions) (Rolfe and Brown, 1997).
asTORi decreased both coupled (30%) and uncoupled respira-
tion (40%) (Figures 3B and 3C). The fraction of cellular respira-
tion dedicated to coupling and uncoupling remained constant
between asTORi- and vehicle-treated cells (Figure 3D). Similaretabolism 18, 698–711, November 5, 2013 ª2013 Elsevier Inc. 699
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Figure 1. Genome-wide Analysis Indicates that Translation of a Subset of mRNAs Encoding Mitochondria-Related Proteins Is Selectively
Suppressed by asTORi
(A) Cellular processes regulated by genes that are translationally suppressed by asTORi PP242 were determined by GAGE analysis. Significantly enriched
mitochondrial related functions were selected and are shown together with their associated enrichment false discovery rates (FDR).
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Figure 2. Translation Regulation of Mito-
chondrial Proteins by mTOR
(A) Levels of proteins in cells treated with the
indicated compounds for 12 hr were determined
by western blotting. eIF4E and b-actin were used
as loading controls.
(B) m7GTP pull-down assay of proteins from
extracts in (A).
(C) Polysome profiles of cells treated with vehicle,
Ink1341, or Torin1 for 12 hr. Absorbance at 254 nm
was recorded continuously. 40S, 60S, and 80S
denote the positions of corresponding ribosomal
subunits and monosomes.
(D) Distribution of ATP5O, ATP5D, TFAM, and
b-actin mRNAs across the density gradients from
(C) was determined by RT-sqPCR. See also
Figure S1.
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mTORC1/4E-BP Controls Mitochondrial Functionfindings were obtained in mouse embryonic fibroblasts (MEFs)
(Figures S2A–S2D), thus indicating that the effects of asTORi
on respiration are not limited to malignant cells. Therefore,
asTORi exert a general effect on cellular energy production by
suppressing respiration in proliferating cells.
Since our data showed that asTORi inhibited mRNA transla-
tion and mitochondrial respiration, we asked whether asTORi
also change the steady-state levels of metabolites involved in
major bioenergetic pathways. Intracellular metabolite levels in
MCF7 cells were measured using gas chromatography-mass
spectrometry (GC-MS) and 1H nuclear magnetic resonance
(NMR) spectroscopy. Ink1341 and PP242 strongly reduced
tricarboxylic acid (TCA) cycle intermediates as compared to
control (Figures 3E and S2E). This striking decrease in TCA cycle
intermediates, in conjunction with diminished respiration, indi-
cates reduced mitochondrial functions. asTORi also induced
intracellular accumulation of glucose (58%) and decreased
lactate and pyruvate (51% and 45%, respectively; Figures S2F(B) A subset of mRNAs encoding mitochondrial proteins that are translationally suppressed following 12 h
decrease relative to control is indicated).
(C) Kernel density plot shows a comparison of fold changes (PP242 versus vehicle treatment) in the upstream
transcription) that are reflected in steady-state mRNA levels (blue line) or translation (black line) for the subse
‘‘translation’’ curve toward ordinate compared to that observed for steady-state mRNA levels indicates that
genes described in Table S1 occurs mostly at the translational level, whereas the contribution of the upstream
transcription) is minimal. See also Table S1.
Cell Metabolism 18, 698–711,and S2G), which is consistent with the
stimulatory role of mTOR in glycolysis
(Du¨vel et al., 2010; Hagiwara et al.,
2012; Yuan et al., 2012). To investigate
the effects of asTORi on carbon flux
through glycolysis and the TCA cycle,
we cultured cells in a medium containing
the uniformly labeled D[U-13C]glucose
for 30 min and measured 13C enrichment
of intracellular metabolites by GC-MS
(Figures 3F, S2H, and S2I) (Nanchen
et al., 2007). In the cytosol, D[U-13C]
glucose through glycolysis produces py-
ruvate m+3 (pyruvate mass shift by three
units from 13C), which is translocated tothe mitochondria or metabolized to lactate m+3 (Figure S2H).
In the mitochondria, pyruvate m+3 is converted to acetyl-CoA
(coenzyme A) m+2, which enters the TCA cycle to produce cit-
ratem+2 upon reaction with oxaloacetate (Figure S2H). Process-
ing of citrate m+2 in the second round of the TCA cycle produces
citrate m+4 (Figure S2H). In vehicle-treated cells, most citrate
molecules contained glucose-derived 13C (Figure 3F, upper). In
Ink1341-treated cells, the proportion of citrate m+4 was dramat-
ically decreased, and the one citrate m+2 was also decreased,
while the one unlabeled citrate (m+0) was increased (Figure 3F,
upper). The proportion of isocitrate m+2 and m+4 as well as
a-ketoglutarate m+2 and m+4 were also diminished in
Ink1341-treated cells (Figure 3F, lower). Furthermore, Ink1341
increased the proportion of unlabeled pyruvate and lactate
(m+0) (Figure S2I). These data show that mTOR activity regulates
the flux of glucose through TCA cycle and glycolysis. In addition,
asTORi treatment decreased mitochondrial DNA content and
mitochondrial mass (Figures 3G–3I). Finally, cellular ATPr treatment with PP242 (FDR < 0.05; percentage
mechanisms of regulation of gene expression (e.g.,
t of genes described in Table S1. Stronger shift of
after 12 hr of PP242 treatment, downregulation of
mechanisms of regulation of gene expression (e.g.,
November 5, 2013 ª2013 Elsevier Inc. 701
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Figure 3. asTORi Suppress Mitochondrial Functions and ATP Production
(A–D)Totalmitochondrial respiration (A),ATP turnover (B),proton leak (C), andcoupled/uncoupled respiration ratio (D) incells treatedwithvehicle,PP242, or Ink1341
for 12 hr were measured using a Clark-type electrode. ATP turnover and proton leak represent oligomycin-sensitive and -insensitive respiration, respectively.
(E) Quantification of levels of TCA cycle intermediates (citrate, a-ketoglutarate, succinate, fumarate, and malate) from cells treated with vehicle or Ink1341.
Metabolites were extracted, profiled by GC-MS, and normalized to cell number.
(F) Mass isotopomer distribution analysis of citrate, isocitrate, and a-ketoglutarate in cells described in (E). Cells were incubated with D[U-13C]glucose, and
isotopomers with the indicated mass shift were analyzed.
(G) Relative mitochondrial DNA content from cells treated with vehicle, Ink1341, or Torin1 for 24 hr was determined by qPCR. Mitochondrial DNA content was
normalized to genomic DNA content.
(H and I) Mitochondrial mass in cells described in (G) was estimated by monitoring mean fluorescence intensity of MitoTracker by flow cytometry.
(J) Quantification of cellular levels of ATP in cells described in (E). Metabolites were extracted, profiled by LC-MS, and normalized to cell number. Data represent
mean ± SD of three independent experiments, except for (E) and (F), where a representative experiment of three independent experiments (each carried out in
triplicate) is presented. *p < 0.05. **p < 0.01. See also Figure S2.
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mTORC1/4E-BP Controls Mitochondrial Functionconcentration was measured by liquid chromatography-mass
spectrometry (LC-MS). Consistent with the downregulation of
mitochondrial functions and glycolysis, a significant decrease
(30%) in the ATP pool was observed in asTORi-treated cells702 Cell Metabolism 18, 698–711, November 5, 2013 ª2013 Elsevieras compared to control (Figure 3J). These findings imply that
the inhibition of mitochondria-associated mRNA translation by
asTORi results in downregulation of TCA cycle activity and
ATP production capacity.Inc.
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Figure 4. mTORC1-Dependent Regulation of Mitochondrial Function and ATP Production
(A) Levels and phosphorylation status of the indicated proteins in MCF7 cells transduced with control, raptor, or rictor shRNA were determined by western
blotting. b-actin and eIF4E were used as loading controls.
(B–E) Total mitochondrial respiration (B), ATP turnover (C), proton leak (D), and coupled/uncoupled respiration rate (E) in cells described in (A) were determined
using a Clark-type electrode.
(F) Levels of pyruvate, lactate, and TCA cycle intermediates (citrate, a-ketoglutarate, succinate, and fumarate) from cells in (A). Metabolites were extracted,
profiled by GC-MS, and normalized to cell number.
(G) Relative mitochondrial DNA content from cells described in (A) was assessed by qPCR. Mitochondria DNA content was normalized to genomic DNA content.
(H) Quantification of cellular ATP levels from cells described in (A). ATP levels were normalized to cell number. Data represent mean ± SD of three independent
experiments. For (F), a representative experiment of three independent experiments (each carried out in triplicate) is presented. *p < 0.05. **p < 0.01.
Cell Metabolism
mTORC1/4E-BP Controls Mitochondrial FunctionmTORC1, but Not mTORC2, Induces Expression of
Nucleus-Encoded Mitochondrial Proteins and
Mitochondrial Function
To determine which mTOR complex is a major regulator of mito-
chondrial function, MCF7 cells were depleted of raptor or rictor,
which are specific components of mTORC1 and mTORC2,Cell Mrespectively (Figure 4A). Raptor depletion decreased the phos-
phorylation of S6K, 4E-BP1, and 4E-BP2,while rictor knockdown
reduced the phosphorylation of Akt (Figure 4A) (Sarbassov et al.,
2005). Depletion of raptor, but not rictor, caused a decrease in
ATP5O and TFAM proteins (Figure 4A). Depletion of raptor was
paralleled by the reduction in mitochondrial respiration (Figuresetabolism 18, 698–711, November 5, 2013 ª2013 Elsevier Inc. 703
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E F
Figure 5. Constitutive mTORC1 Activation
Stimulates Mitochondrial Function and
ATP Production
(A) Levels and phosphorylation status of the indi-
cated proteins in WT and TSC2 KO MEFs were
determined by western blotting. b-actin was used
as a loading control.
(B) Polysome profiles of cells described in
(A). Absorbance at 254 nm was continuously re-
corded. 40S, 60S, and 80S denote the corre-
sponding ribosomal subunits and monosomes,
respectively.
(C) Polysome distribution of ATP5D, TFAM, and
b-actin mRNAs in cells described in (A) was
determined by RT-sqPCR.
(D) Total mitochondrial respiration, ATP turnover,
and coupled/uncoupled respiration ratio of cells
described in (A) were measured using a Clark-type
electrode.
(E) Relative mitochondrial DNA content from cells
described in (A) was determined by qPCR. Mito-
chondria DNA content was normalized to genomic
DNA content.
(F) Quantification of cellular ATP levels from cells
described in (A). ATP levels were normalized to cell
number. Data represent mean ± SD of three
independent experiments. *p < 0.05. **p < 0.01.
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mTORC1/4E-BP Controls Mitochondrial Function4B–4E) and the amounts of TCA cycle intermediates pyruvate
and lactate (Figure 4F). This indicates that mTORC1 bolsters
mitochondrial function, TCA cycle, and glycolysis. In turn, knock-
down of rictor resulted in a decrease in the amounts of pyruvate
and lactate and stimulation of mitochondrial respiration (Figures
4B–4F), which is consistent with recent reports (Betz et al., 2013;704 Cell Metabolism 18, 698–711, November 5, 2013 ª2013 Elsevier Inc.Hagiwara et al., 2012; Schieke et al.,
2006; Yuan et al., 2012). Interestingly,
depletion of rictor also decreased the
amount of a-ketoglutarate (Figure 4F). In
MCF7 cells, the majority of a-ketogluta-
rate (70%) was unlabelled (Figure 3F).
This suggests that in MCF7 cells, a-keto-
glutarate is derived from other metabolic
pathways such as glutaminolysis (Ward
and Thompson, 2012), thereby suggest-
ing that mTORC2 may regulate this pro-
cess. In addition, raptor knockdown
diminished intracellular ATP levels and
mtDNA content relative to control,
whereas depletion of rictor had no effect
(Figures 4G and 4H). These findings indi-
cate that the effects of mTOR signaling
on mitochondrial biogenesis and func-
tions are mostly mediated by mTORC1.
Ras-homolog enriched in brain (Rheb)
is a small GTPase that activates mTORC1
(Inoki et al., 2003; Tee et al., 2003). Tuber-
ous sclerosis complex (TSC1/2) acts as a
GAP toward Rheb, thereby suppres-
sing mTORC1 signaling (Laplante and
Sabatini, 2012). We used TSC2 knockout(KO) MEFs (Zhang et al., 2003) to determine the effects of
mTORC1 hyperactivation onmitochondrial biogenesis and func-
tions. As expected, TSC2 KO MEFs exhibited elevated phos-
phorylation of 4E-BP1 and S6K1 as compared to wild-type
(WT) cells (Figure 5A). Moreover, levels of ATP5D and TFAM pro-
teins were also higher in TSC2 KO than in WT MEFs (Figure 5A).
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polysomes was higher in TSC2 KO as compared to WT MEFs
(Figure 5B) (Conn and Qian, 2013; Sun et al., 2011). Importantly,
ATP5D and TFAM but not b-actin mRNAs were shifted toward
heavy polysome fractions in TSC2 KO as compared to WT
MEFs, indicating that loss of TSC2 selectively bolsters transla-
tion of ATP5D and TFAM mRNAs (Figure 5C). Consistent with
previous findings (Cunningham et al., 2007; Schieke et al.,
2006), loss of TSC2 expression increased mitochondrial respira-
tion, mitochondrial DNA content, and ATP levels (Figures 5D–
5F). These results further support the conclusion that mTORC1
modulates mitochondrial activity and biogenesis by stimulating
translation of a subset of mitochondria-related mRNAs.
4E-BPs Are Mediators of mTORC1-Dependent Control
of Mitochondrial Function
4E-BPs are implicated in the regulation of mitochondrial function
in Drosophila and mammals (Goo et al., 2012; Zid et al., 2009).
Therefore, we investigated the role of 4E-BPs in mediating the
effects of asTORi on translation of mitochondria-related mRNAs.
To this end, we depleted 4E-BP1 and 4E-BP2 (4E-BP1/2) from
MCF7 cells. asTORi impaired global mRNA translation to a
higher extent in control versus 4E-BP1/2-depleted cells, as illus-
trated by a stronger increase in the 80S monosome peak and a
decrease in polysomes (Figure 6A).Whereas 4E-BP1/2 depletion
did not affect polysome distribution of b-actin mRNA (Figure 6B,
upper), it prevented the Ink1341-induced shift of TFAM and
ATP5O mRNAs toward lighter polysomes (Figure 6B, lower).
Therefore, 4E-BPs act as major mediators of mTORC1 on trans-
lation of TFAM and ATP5O mRNAs. Accordingly, asTORi
decreased ATP5O and TFAM protein levels in control, but not
in 4E-BP1/2-depleted cells (Figure 6C).
We next studied the effects of 4E-BPs on mitochondrial
respiration. Although depletion of 4E-BPs did not affect mito-
chondrial respiration in untreated MCF7 cells (Figure S3A), it
significantly relieved asTORi-induced inhibition of this process
as compared to a control (Figure 6D). Parallel results were
obtained with 4E-BP1 and 4E-BP2 double knockout (4E-BP
DKO) MEFs (Figures S3B and S3C). To investigate the impact
of 4E-BP1/2 depletion on mTORC1-dependent regulation of
TCA cycle, we performed glucose flux analyses (Figures 6E
and S3D). In control cells, Ink1341 diminished the proportion of
13C-labeled TCA cycle intermediates, which was accompanied
by an increment of unlabeledmetabolites (Figure 6E). In contrast,
carbon flux of TCA cycle intermediates in 4E-BP1/2-depleted
cells was partially resistant to Ink1341 as compared to control
cells (Figure 6E). Ink1341 also reduced carbon flux from glucose
to pyruvate and lactate in control cells, but less so in 4E-BP1/2-
depleted cells (Figure S3D). Finally, depletion of 4E-BPs miti-
gated the effects of asTORi onmitochondrial DNA content, mito-
chondrial mass, and intracellular ATP levels (Figures 6F–6H).
These findings show that the inhibition of mitochondrial activity
andbiogenesis by asTORi is predominantlymediatedby4E-BPs.
S6Ks, PGC-1a, and HIF-1a Are Not Major Mediators of
the Effects of Short-Term mTOR Inhibition on
Mitochondria
In addition to 4E-BPs, S6Ks alsomediate the effects of mTORC1
on translation (Roux and Topisirovic, 2012). Using S6K1/2 dou-Cell Mble knockout (S6K DKO) MEFs and S6K DKO MEFs in which
expression of S6K1 and 2 was reconstituted (Figure S4A)
(Dowling et al., 2010), we show that neither under basal condi-
tions nor in response to asTORi treatment do S6Ks affect mito-
chondrial respiration and glucose flux to pyruvate and lactate
(Figures S4B–S4E). However, loss of S6K expression resulted
in decreased glucose flux to citrate under basal conditions (Fig-
ure S4F) and attenuated inhibitory effects of asTORi on citrate
production (Figure S4H). Citrate metabolism plays a key role in
fatty acid synthesis, and it has been reported that S6Ks aremajor
mediators of mTOR function in lipogenesis (Du¨vel et al., 2010).
Therefore, it is likely that S6Ks modulate citrate production
downstream of mTORC1 in conjunction with their role in lipid
synthesis. Nonetheless, these results demonstrate that S6Ks
are not major mediators of mTORC1 function in mitochondrial
biogenesis and activity.
Although PGC-1a deficiency (Figure S5A) impaired mitochon-
drial respiration (Figure S5B), asTORi inhibited this process to a
similar extent in WT and PGC-1a KO MEFs (Figure S5C). HIF-1a
deficiency did not affect basal mitochondrial respiration (Fig-
ure S5E) or influence the effects of asTORi on mitochondrial
respiration and glucose flux (Figures S5F and S5G). Therefore,
PGC-1a and HIF-1a do not appear to be required for the sup-
pression of mitochondrial function that is observed after 12 hr
of mTOR inhibition.
4E-BPs and Autophagy Independently Mediate the
Effects of asTORi on Mitochondria
mTORC1 inhibition activates autophagy, which is a major
pathway of degradation of mitochondria (Fleming et al., 2011).
To investigate the possible role of autophagy in mediating the
effects of asTORi treatment on mitochondria, we generated
WT and 4E-BP DKO MEFs in which autophagy was impaired
by ATG5 depletion (Figure S6A). As expected, asTORi induced
autophagy in control cells as illustrated by a reduction in
LC3A-I and concomitant increase in LC3A-II, but not in ATG5-
depleted cells (Figure S6A). ATG5 reduction partially relieved
the effects of asTORi on mitochondrial DNA content and mass
in WT MEFs (Figures S6B–S6D). Strikingly, ATG5 depletion in
4E-BP DKO MEFs rescued the reduction caused by asTORi on
mitochondrial DNA content and mass (Figures S6B–S6D). These
findings indicate that translational regulation through 4E-BPs
and autophagy collaboratively mediate the effects of mTORC1
on mitochondria.
Re-expression of TFAM Attenuates the Effects
of asTORi on Mitochondrial DNA Synthesis
TFAM promotes mitochondrial biogenesis by stimulating mito-
chondrial DNA replication and transcription (Bonawitz et al.,
2006). To determine whether suppression of TFAM translation
underlies the effects of the mTORC1/4E-BP pathway on mito-
chondrial biogenesis, we used a TFAM cDNA lacking its 50
UTR whose expression is resistant to asTORi treatment (Fig-
ure S7A). Consistent with previous findings (Bonawitz et al.,
2006), TFAM overexpression increased basal mitochondrial
DNA content (Figure S7B). More importantly, TFAM overexpres-
sion attenuated the effects of Ink1341 on mitochondrial DNA
content (Figure S7C). These data indicate that suppression of
TFAM expression at the level of translation plays a major roleetabolism 18, 698–711, November 5, 2013 ª2013 Elsevier Inc. 705
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Figure 6. 4E-BPs Are Required for mTOR-Dependent Mitochondrial Function and Translation of mRNAs Encoding Mitochondrial Proteins
(A) Polysome profiles of MCF7 cells transduced with a control or 4E-BP1/2 shRNA and treated with Ink1341 or Torin1 for 12 hr. Absorbance at 254 nm was
continuously recorded. 40S, 60S, and 80S denote the corresponding ribosomal subunits and monosomes, respectively.
(B) Polysome distribution of ATP5O, TFAM, and b-actin mRNAs in cells described in (A) was determined by RT-sqPCR.
(C) Levels and phosphorylation status of the indicated proteins in cells described in (A) and treated with asTORi were determined by western blotting.
(legend continued on next page)
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Figure 7. The 4E-BP-Dependent Effect of
asTORi onRespiration In Vivo andProposed
Model of Cross-Regulation of mRNA Trans-
lation and Energy Metabolism
(A) Oxygen consumption of WT and 4E-BP DKO
mice with intraperitoneal administration of vehicle
or Ink1341 (3 mg/kg body weight). Oxygen con-
sumption was measured over 24 hr, and average
oxygen consumption per hour during dark phase
was normalized to body mass (see Experimental
Procedures).
(B) Locomotor activity measured by photobeam
breaks.
(C) Heat production calculated with a calorific
value based on the observed respiratory exchange
ratio and themeasured oxygen consumption. Data
represent mean ± SD. n = 5 per group. *p < 0.05.
**p < 0.01.
(D) Model of translational control of mitochondrial
function: mTORC1 prevents 4E-BPs from binding
to eIF4E and promotes translation of mRNAs
encoding mitochondria-related proteins, thereby
bolstering mitochondrial energy production. This
increase in mitochondrial ATP production fuels
mRNA translation, which is one of the most en-
ergy consuming processes in the cell. Energy
balance between consumption and production is
therefore maintained via the mTORC1/4E-BP
pathway.
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synthesis.
mTORC1 Controls Mitochondrial Respiration through
4E-BP Inhibition In Vivo
mTORC1 signaling controls oxygen consumption in mice
(Polak et al., 2008; She et al., 2007). To investigate the effects
of asTORi on in vivo respiration, WT and 4E-BP DKO mice
were treated daily with Ink1341 for 2 weeks. Ink1341 inhibited
23% oxygen consumption in WT, but not in 4E-BP DKO mice
(Figure 7A). Consistent with a recent finding that a tissue-
specific raptor knockout mouse exhibits decreased locomotor
activity (Bentzinger et al., 2008; Polak et al., 2008), Ink1341
suppressed locomotor activity in WT mice, whereas this(D) Total mitochondrial respiration, ATP turnover, proton leak, and coupled/uncoupled respiration rate of cell
were determined using a Clark-type electrode.
(E) Mass isotopomers distribution analysis of citrate, isocitrate, and a-ketoglutarate in cells described in
incubated with D[U-13C]glucose, and isotopomers with the indicated mass shift were analyzed by GC-MS.
(F) Relative mitochondrial DNA content from cells described in (A) and treated with asTORi for 24 hr was dete
normalized to genomic DNA content.
(G) Mitochondrial mass in cells described in (A) treated with asTORi for 24 hr was estimated by monitoring m
cytometry.
(H) Quantification of cellular ATP levels in the cells described in (E). Data represent mean ± SD
representative experiment of three independent experiments (each carried out in triplicate) is presented. *p <
and S7.
Cell Metabolism 18, 698–711,effect was absent in 4E-BP DKO mice
(Figure 7B). Also, Ink1341 suppressed
heat production in WT, but not in 4E-
BP DKO mice (Figure 7C). Thus, consis-
tent with the in vitro findings, mTORC1controls mitochondrial respiration and energy metabolism
through 4E-BPs in vivo.
DISCUSSION
In this study we describe a feed-forward mechanism whereby
translation of nucleus-encoded mitochondria-related mRNAs is
modulated via the mTORC1/4E-BP pathway to induce mito-
chondrial ATP production capacity and thus provide sufficient
energy for protein synthesis (Figure 7D).
Hyperactivation of mTOR signaling is frequently observed in
cancer (Laplante and Sabatini, 2012), and eIF4E overexpression
is tumorigenic in vitro and in vivo (Avdulov et al., 2004; Lazaris-
Karatzas et al., 1990; Ruggero et al., 2004; Wendel et al.,s described in (A) and treated with asTORi for 12 hr
(A) and treated with asTORi for 12 hr. Cells were
rmined by qPCR. Mitochondrial DNA content was
ean fluorescence intensity of MitoTracker by flow
of three independent experiments. For (E), a
0.05. **p < 0.01. See also Figures S3, S4, S5, S6,
November 5, 2013 ª2013 Elsevier Inc. 707
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effect) is a hallmark of cancer cells (Vander Heiden et al.,
2009), these cells also rely on mitochondrial intermediates to
generate building blocks (e.g., nucleic acids and phospholipids)
necessary for neoplastic growth (Ward and Thompson, 2012).
The mTORC1/4E-BP pathway promotes ATP production
capacity by mitochondria, as well as cell cycle progression
(Dowling et al., 2010). Thus, mTORC1 drives cell proliferation
and neoplastic growth by simultaneously activating translation
of mRNAs that encode proteins involved in cellular energy pro-
duction and cell cycle progression.
Notably, in spite of the reduced ATP utilization caused by the
inhibition of protein synthesis, an increase in cellular ATP con-
centration was not observed after mTOR inhibition (Figure 3J),
which can be explained by the concomitant reduction in mito-
chondrial respiration (Figure 3B). Indeed, asTORi-induced
impairment in ATP production is accompanied by reduction in
ATP consumption, which results in a state of metabolic quies-
cence. These data suggest that asTORi may induce a state of
‘‘metabolic dormancy’’ in cancer cells, which would predict a
cytostatic rather than cytotoxic effect of asTORi in the clinic
(Benjamin et al., 2011).
mTOR is a multifaceted kinase that employs a number of
effectors to exert its biological functions (Laplante and Sabatini,
2012). Accordingly, 4E-BPs affect TCA cycle in conjunction
with other mTORC1 targets (e.g., S6Ks; Figures S4F and
S4H) and mTORC2 (Figure 4F) that have been previously re-
ported to modulate lipogenesis and glycolysis (Du¨vel et al.,
2010; Hagiwara et al., 2012; Yuan et al., 2012). However, our re-
sults demonstrate that 4E-BPs act as major mediators of the
effects of mTORC1 on mitochondrial biogenesis and function.
In addition to stimulation of mitochondrial biogenesis by antag-
onizing 4E-BP-dependent translational repression of mito-
chondria related mRNAs, mTORC1 inhibits mitochondrial
degradation by suppressing autophagy (Figures S6B–S6D).
These findings suggest coordination of translational and auto-
phagy programs that underpin important biological effects of
mTORC1 signaling.
mTORC1 also stimulates mitochondrial respiration and
biogenesis via the transcriptional regulators PGC-1a and HIF-
1a (Cunningham et al., 2007; Du¨vel et al., 2010). However,
neither PGC-1a nor HIF-1a appeared to impair mitochondrial ac-
tivity after 12 hr inhibition of mTOR (Figure S5). Accordingly, we
did not observe major changes in mRNA steady-state levels of a
subset of mitochondria-related genes as a consequence of
mTOR inhibition (Figure 1C). It is well established that the
changes in gene expression that occur at the level of transcrip-
tion are heralded by those that take place at the posttranscrip-
tional level (Anderson, 2010). Therefore, it is likely that
mTORC1-dependent changes in translation of mitochondria-
related mRNAs precede transcriptional regulation. PGC-
1a-dependent transcriptional change of mitochondria-related
genes was observed in myoblasts in which mTORC1 was in-
hibited for at least 16 hr (Bla¨ttler et al., 2012). Moreover, mito-
chondria-related genes whose expression is regulated by
mTORC1 at the level of translation (ATP5O and ATP5D) were
not identified as transcriptional targets ofmTORC1 (Cunningham
et al., 2007). Hence, it is conceivable that mTOR drives mito-
chondrial function by simultaneously orchestrating translational708 Cell Metabolism 18, 698–711, November 5, 2013 ª2013 Elsevierand transcriptional programs to modulate expression of mito-
chondria-related genes.
Two recent studies suggested that the inhibition of mTORC1
by asTORi suppresses 50 TOP mRNA translation in a 4E-BP-
dependent manner (Hsieh et al., 2012; Thoreen et al., 2012).
Herein, using a battery of well-established biochemical and
functional assays, we demonstrate that the mTORC1/4E-BP
pathway stimulates mitochondrial functions by enhancing the
translation of a subset of mitochondria-related mRNAs, which
largely do not harbor 50 TOP elements.
In summary, we demonstrate that the mTORC1/4E-BP
pathway controls cellular energy homeostasis via translation of
nucleus-encoded mitochondria-related genes. This uncovers
an important mechanism that explains the role of mTOR
signaling in diseases characterized by metabolic perturbations,
such as cancer.
EXPERIMENTAL PROCEDURES
Genome-wide Analysis of mRNA Translation Following Treatment
with PP242
We used data sets containing steady-state and polysome-associated mRNA
obtained from MCF7 cells treated with vehicle or PP242 for 12 hr from our
previous study that were deposited at the Gene Expression Omnibus (GEO,
GSE36847) (Larsson et al., 2012). Differential translation was calculated using
anota analysis (Larsson et al., 2010, 2011), which corrects changes in poly-
some-associated mRNA for changes in cytoplasmic steady-state mRNA.
We used GAGE (Luo et al., 2009) to identify cellular processes (as defined
by the Gene Ontology Consortium) showing a significant gene set enrichment
among genes that were translationally suppressed (using data from the anota
analysis) following treatment with PP242. We applied the ‘‘rank.test’’ option in
GAGE using signed (direction of regulation) log10(FDR) as input data within
the ‘‘gage’’ bioconductor package (Gentleman et al., 2004). Cellular processes
that showed an enrichment in FDR < 0.05 and were related to mitochondrial
function were selected (shown in Figure 1A). We also compared fold changes
(PP242 treatment versus control) in steady-state mRNA levels and translation
activity (i.e., obtained by anota analysis) for the subset of mitochondrial genes
that were identified as differentially regulated at the level of translation
following treatment with PP242. Kernel densities for the observed fold
changes (PP242 versus vehicle treatment) were obtained using the ‘‘density’’
function in ‘‘R’’ (http://www.r-project.org) with default settings and presented
in Figure 1C.
Cell Culture, Lentivirus shRNA Silencing, and mTOR Inhibitors
Cell culture and lentivirus shRNA silencing were carried out as described
(Dowling et al., 2010). The information about all MEFs is described in Supple-
mental Experimental Procedures. For lentivirus production, lentiviral vectors
were cotransfected into HEK293T cells with the lentivirus packaging plasmids
PLP1, PLP2, and PLP-VSVG (Invitrogen) using Lipofectamine (Invitrogen).
Supernatants were collected 48 and 72 hr postinfection, passed through a
0.45 mm nitrocellulose filter, and applied on target cells with polybrene
(1 mg/ml). Cells were reinfected the next day and selected with puromycin
(5 mg/ml) for 48 hr. The information about lentiviral vectors is described in Sup-
plemental Experimental Procedures. PP242 and Ink1341 were provided by
Intellikine, and Torin1 was obtained from Tocris Bioscience. For all experi-
ments, cells were seeded at 50% confluency, grown overnight, and treated
with vehicle (DMSO), PP242 (2.5 mM), Ink1341 (250 nM), or Torin1 (250 nM).
Polysome Profiling, RNA Isolation and RT-sqPCR
Polysome profiling and RT-sqPCR were carried out as described (Dowling
et al., 2010). Briefly, cells were cultured in 15 cm dishes, treated with the indi-
cated drugs or vehicle for 12 hr, washed twice with cold PBS containing
100 mg/ml cycloheximide, collected, and lysed in 450 ml of hypotonic buffer
(5mMTris-HCl [pH 7.5], 2.5mMMgCl2, 1.5mMKCl, 100 mg/ml cycloheximide,
2 mMDTT, 0.5% Triton X-100, and 0.5% sodium deoxycholate). Lysates wereInc.
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KOH [pH 7.6], 100 mM KCl, and 5 mM MgCl2) and centrifuged at
36,000 rpm (SW 40 Ti rotor, Beckman Coulter, Inc.) for 2 hr at 4C. Gradients
were fractionated and optical density at 254 nm was continuously recorded
using an ISCO fractionator (Teledyne ISCO). RNA from each fraction and input
was isolated using TRIzol (Invitrogen) according to the manufacturer’s instruc-
tions. RT-sqPCR reactions were carried out using SuperScript III First-Strand
Synthesis System (Invitrogen) and iQ SYBR Green Supermix (Bio-Rad) ac-
cording to themanufacturers’ instructions. The list of primers is provided in Ta-
ble S3.
Cell Lysis, Western Blotting, and Cap (m7GDP) Pull-Down Assay
Cells were lysed in lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM
EDTA, 1% NP-40, Roche complete protease inhibitor cocktail). Protein con-
centrations were estimated with the Bio-Rad protein assay, and western
blotting was carried out as described (Dowling et al., 2010). The information
about antibodies is described in Supplemental Experimental Procedures.
Cap pull-down assay was carried out as described (Dowling et al., 2010).
Briefly, cells were lysed by three freeze-thaw cycles in the cap pull-down buffer
(50mMHEPES-KOH [pH 7.5], 150mMKCl, 1mMEDTA, 2mMDTT, and 0.2%
Tween-20) containing protease inhibitors. Protein extract (1 mg) was incu-
bated for 2 hr at 4C with m7GDP-agarose beads. After incubation, beads
were washed five times with the cap pull-down buffer and eluted by boiling
in the presence of 13 sample buffer for 5 min. m7GDP-bound proteins were
visualized by western blotting.
Respiration Assay
The respiration assay was carried out as described (Eichner et al., 2010).
Briefly, cells were cultured in 10 cm or 15 cm dishes, treated with the indicated
drugs or vehicle for 12 hr, trypsinized, and resuspended in PBS supplemented
with 25 mM glucose, 1 mM pyruvate, and 2% BSA. A TC10 automated cell
counter assessed total cell count and cell viability via Trypan blue dye exclu-
sion (Bio-Rad). A total of 2.0 3 106 cells were placed in the chamber of a
Clark-type oxygen electrode, and cellular respiration wasmeasured. Oligomy-
cin-sensitive respiration represents ATP turnover. Oligomycin-insensitive
respiration represents proton leak. Myxothiazol was added to quantify nonmi-
tochondrial respiration. In all experiments performed, nonmitochondrial respi-
ration was undetectable.
Mitochondrial DNA Quantification and Mitochondrial Mass
Quantification
The mitochondrial DNA quantification assay was carried out as described
(Cunningham et al., 2007). Briefly, cells were treated with the indicated drugs
or vehicle for 24 hr. Genomic and mitochondrial DNA was extracted using
DNeasy Blood and Tissue kit (QIAGEN). Genomic and mitochondrial DNA
was quantified by qPCR using iQ SYBR Green Supermix (Bio-Rad). The list
of primers is provided in Table S3.
For the quantification of mitochondrial mass, drug-treated cells were trypsi-
nized, washed with PBS twice, and stained with 10% FBS-DMEM containing
500 nMMitoTracker Deep Red FM (Invitrogen) for 30 min at 37C. MitoTracker
fluorescence intensities were analyzed by FACS (BD). Relative mean fluores-
cence intensities were calculated by FlowJo (Tree Star, Inc.) and used to deter-
mine mitochondrial mass.
LC-MS, NMR, and Mass Isotopomer Distribution Analysis by GC-MS
LC-MS and NMR analyses and mass isotopomer distribution analysis are
described in Supplemental Experimental Procedures. Briefly, for LC-MS and
NMR analyses, cells were treated with vehicle or asTORi for 12 hr, and metab-
olites were extracted and analyzed by LC-MS or NMR. For mass isotopomer
distribution analysis, cell were treated with vehicle or asTORi for 12 hr and
washed with PBS, and media containing 10% dialyzed FBS and 5.55 mM D
[U-13C]glucose (Cambridge Isotope Laboratories) was added for 30 min. Cells
were washed with ice-cold normal saline solution, and metabolites were
extracted and analyzed by GC-MS.
In Vivo Metabolic Studies
In vivo metabolic studies are described in Supplemental Experimental Proce-
dures. Briefly, eachmousewas housed in a separate cage andmaintained on aCell M12 hr dark-light cycle with access to food and water ad libitum. For asTORi
treatment, Ink1341 was formulated in 5% NMP (1-methyl-2-pyrrolidinone),
15% polyvinylpyrrolidone K30, and 80% water and administrated intraperito-
neally at 3 mg/kg body weight daily for 2 weeks. Oxygen consumption, loco-
motor activity, and heat production were determined with an Oxymax-CLAMS
system (Columbus Instruments) according to the manufacturer’s instruction.
All mouse experiments were carried out in accordance with the guidelines
for animal use issued by the McGill University Animal Care Committee.Statistical Analysis
All values represent mean ± standard deviation (SD) of three independent
experiments (unless otherwise indicated). Differences between groups were
examined for statistical significance using Student’s t test (two-tailed dis-
tribution with two-sample equal variance). We considered a p value
of < 0.05 statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
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